FLII and neoplasm: Comprehensive drug screening (130 compounds) across 639 human tumor cell lines by Garnettet al.57 identified a highly significant association between the presence of the EWS/FLI rearrangement and olaparib (Lynparza) sensitivity (geometric mean IC50 for EWS/FLI = 4.7 versus 64 μM for non-EWS/FLI lines).